Researchers at New York University Abu Dhabi (NYUAD) have developed a breakthrough ingestible device that could provide a non-drug alternative to popular weight-loss medications like Ozempic. The device, called ICOPS (Ingestible Controlled Optogenetic Stimulation), is a tiny 3D-printed capsule equipped with a light-emitting diode (LED) that can be activated wirelessly using magnetic fields.
Once ingested, the capsule travels naturally through the digestive system, emitting light to stimulate specific neurons in the gut. This process can potentially influence appetite and nutrient absorption, offering a drug-free approach to weight management.
ICOPS uses optogenetics, a technique that makes certain neurons sensitive to light. In preclinical studies with rats, the device successfully activated these neurons, showing promise for non-invasive treatment of metabolic and digestive disorders. The wireless design eliminates the need for batteries, allowing safe and efficient operation within the body.
While current research is limited to animal models, the implications for human health are significant. If adapted for human use, ICOPS could transform obesity treatment by regulating appetite without injections or daily medications. This development comes amid growing interest in alternatives to drugs like Ozempic, which have surged in popularity for weight loss.
The NYUAD team, led by Dr. Khalil Ramadi, Assistant Professor of Bioengineering, plans to expand the device’s capabilities to include targeted drug delivery and electrical stimulation. The research has been published in Advanced Materials Technologies, highlighting a major advancement in biomedical engineering.
This innovative device could offer a safer, more convenient solution for patients managing obesity and related metabolic conditions, positioning NYU Abu Dhabi at the forefront of medical technology and research innovation.
